Search Results for 'Dor Nrti'

Dor Nrti published presentations and documents on DocSlides.

DTG-Based Regimens Are Active in INI-Naive Patients With a

trish-goza
14 Slides

Jim Demarest. ,. 1. Mark Underwood,. 2. Marty S...

Switch to LPV/

lindy-dunigan
6 Slides

r. + 3TC. OLE . Study. LPV/. r. bid + 3TC or FT...

NRTI-sparing

min-jolicoeur
27 Slides

SPARTAN. PROGRESS. NEAT001/ANRS 14. 3 . MODERN. R...

Crafting an ART Regimen for Initiation or Salvage:

mitsue-stanley
18 Slides

Are NRTI’s Necessary?. Brian R. Wood, MD. Assis...

HIV Drug Resistance in Well-Resourced Settings

faustina-dinatale
23 Slides

Vincent Marconi, . MD. Outline. Transmitted Drug ...

Comparison of INSTI vs PI

conchita-marotz
17 Slides

FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . De...

Comparison of NRTI combinations

tawny-fly
20 Slides

ZDV/3TC . vs. TDF + FTC. Study 934. ABC/3TC . vs...

Comparison of NNRTI vs PI/r

alexa-scheidler
14 Slides

EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . ...

Management of NRTI Resistance

giovanna-bartolotta
40 Slides

David Spach, MD. Principal . Investigator, NW AET...

NRTI-sparing

liane-varnes
6 Slides

SPARTAN. PROGRESS. RADAR. NEAT001/ANRS 14. 3. A40...

Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine

luanne-stotts
0 Slides

Chief, Division of Infectious Diseases. Weill Med...

Antiretroviral Updates:

tatyana-admore
0 Slides

New Treatments for HIV. C. Ryan Tomlin, . Pharm.D...

Advances and Challenges in HIV Antiretroviral Therapy

stefany-barnette
0 Slides

Camille Angle, Meagan Bardan, Hanna Schimjawicz a...

HIV Pharmacotherapy Focused Update

yoshiko-marsland
0 Slides

Drew Lambert, . PharmD. lambertd@husson.edu. Huss...

Switch a ATV/r 3TC Estudio ATLAS-M

pamella-moone
0 Slides

ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N =...

Phase 2 of new ARVs Fostemsavir

conchita-marotz
0 Slides

, . prodrug. of . temsavir. . (attachment inhib...

Joel E. Gallant, MD, MPH

mastervisa
11 Slides

Medical Director, Specialty . Services. Southwest ...

Switch to LPV/ r + 3TC OLE

susan2
6 Slides

Study. LPV/. r. bid + 3TC or FTC . qd. + NRTI. N ...

Meg Doherty MD MPH PhD 23 July 2018

jordyn
41 Slides

WHO HQ. The role of DTG based regimens in first- a...

HIV Treatment 101 C. Ryan Tomlin, Pharm.D., BCPS, AAHIVP

Powerpixel
42 Slides

Clinical Pharmacist – HIV Medicine. Outline. Wha...

What’s new in the 2019 WHO Guidelines:

elina
32 Slides

Dolutegravir based regimens in first- ad second-li...

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine

reese
5 Slides

TOTEM. Switching the NRTI Backbone to Tenofovir DF...

Switching Antiretroviral Therapy (ART) in Your African American Patients: When and How

taylor
29 Slides

Supported by an educational grant from Gilead Scie...

DTG vs LPV/r (DAWNING): Efficacy

winnie
12 Slides

by Baseline NRTI Resistance . and Second-Line NRTI...

Dolutegravir vs. Raltegravir

zoe
9 Slides

SPRING-2 Study. Dolutegravir. versus Raltegravir....

NRTI-sparing SPARTAN PROGRESS

shepard237
5 Slides

RADAR. NEAT001/ANRS 14. 3 . A4001078. VEMAN. MODER...

Switch PI/R to ETR Etraswitch

dustin869
6 Slides

Etraswitch. . Study. : Switch PI/r to ETR. Contin...